Alnylam collaborator Regeneron secures FDA approval of Livsayis (cemdisiran)
REGN•Regeneron secured FDA approval of Livsayis (cemdisiran), the seventh FDA-approved therapeutic from Alnylam’s RNAi platform in less than nine years. Alnylam will receive $25 million and up to 15% royalties from Regeneron.




